Abbott Files For H pylori Eradication

9 January 1995

Abbott Laboratories has filed a Supplemental New Drug Application in the USA for the use of its clarithromycin antibiotic in combination with Astra/Merck's proton pump inhibitor Prilosec (omeprazole) to eradicate Helicobacter pylori and prevent peptic ulcer recurrence.

In most clinical trials of the combination, a 28-day dosing regimen comprising 500mg clarithromycin tid plus 40mg/day omeprazole for days one to 14 was used, followed by 20mg/day omeprazole for the remainder of the course. Eradication rates of over 70% have been achieved.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight